The GPC1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the GPC1 gene in the HAP1 human cell line. This heterogeneous knockout model provides a pooled culture of loss-of-function variants, avoiding single-clone bias while maintaining effective gene disruption across the population. The polyclonal format is suitable for functional studies where isogenic clonality is not required, offering a robust tool for pathway analysis and phenotypic screening.
The HAP1 cell line is a near-haploid human chronic myeloid leukemia cell model derived from the KBM-7 line. Its haploid karyotype drastically simplifies gene editing because a single targeting event can generate a complete loss-of-function allele, eliminating the need for biallelic modification. This feature, combined with the cell line??s hematopoietic origin and rapid growth kinetics, makes HAP1 an exceptionally tractable platform for high-efficiency CRISPR-based gene disruption and downstream functional genomics analyses.
GPC1 encodes glypican-1, a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan that localizes to the cell surface and acts as a co-receptor for multiple heparin-binding growth factors. It interacts with FGF2, SHH, WNT3A, HGF, and VEGFA, facilitating their presentation to receptors, thereby modulating Wnt/CTNNB1, Hedgehog/GLI1, and FGF/MAPK pathways. Downstream targets include CTNNB1, GLI1, MAPK1, MAPK3, AKT1, and SNAI1. Upstream regulators HIF1A, SHH, WNT3A, FGF2, and TGFB1 control GPC1 expression. Disruption abolishes heparan sulfate-dependent growth factor binding, attenuating multiple signaling axes and compromising cell adhesion mediated by FN1 and LAMC1.
Within the HAP1 leukemic background, GPC1 loss selectively disables growth factor responses that are frequently hyperactivated in myeloid and solid tumors. The near-haploid nature of HAP1 ensures that functional consequences of GPC1 disruption are unmasked, as there are no wild-type alleles to compensate. This allows researchers to interrogate the dependence of cancer-relevant signaling networks on GPC1-mediated ligand presentation, particularly in the context of aberrant Wnt, Hedgehog, and FGF pathway activation. Moreover, since HAP1 cells maintain certain hematopoietic signaling features, the model offers insights into glypican-1??s role in leukemogenesis and the tumor microenvironment.
The GPC1 Knockout HAP1 Polyclonal Cells support applications in cancer biology, drug target validation, growth factor signaling dissection, Wnt/Hedgehog pathway analysis, cell adhesion and migration studies, and haploid genetic screening. Representative assays include western blotting, RT-qPCR, proliferation and migration assays, flow cytometry, co-immunoprecipitation, immunofluorescence, luciferase reporter pathways, and drug sensitivity testing. For further information, please contact Ascent Research.
